HIV-1/hepatitis B coinfection

References

• Rockstroh J, Konopnicki D, Soriano V et al. Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8–11 February 2004 (Abstract 799).
   Google Scholar
• Thio C, Seaberg E, Skolasky R et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 360, 1921–1926 (2002).
   PubMed Web of Science ®Google Scholar
• •Multicenter AIDS Cohort Study is a prospective, longitudinal, cohort study of HIV infection in homosexual and bisexual men in the USA with approximately 5000 enrollees.
   Google Scholar
• Martin-Carbonero L, Soriano V, Valencia E et al. Increased impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res. Hum. Retroviruses 17, 1467–1471 (2001).
   PubMed Web of Science ®Google Scholar
• Benhamou Y. Antiretroviral therapy and HIV/hepatitis B coinfection. Clin. Infect. Dis. 38, S98–S103 (2004).
   PubMed Web of Science ®Google Scholar
• Chung RT, Kim AY, Polsky B. HIV/hepatitis B and C coinfection: pathogenic interactions, natural history, and therapy. Antivir. Chem. Chemother. 12(Suppl. 1), 73–91 (2001).
   PubMedGoogle Scholar
• Puoti M, Spinetti A, Ghezzi A et al. Mortality for liver disease in patients with HIV infection: a cohort study. AIDS 24, 211–217 (2000).
   Google Scholar
• McNair AN, Main J, Thomas HC. Interactions of the human immunodeficiency virus and the hepatotropic viruses. Semin. Liver Dis. 12, 188–196 (1992).
   PubMedGoogle Scholar
• Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin. Infect. Disease. 37, 1678–1685 (2003).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. AASLD Practice guidelines chronic hepatitis B: update of recommendations. Hepatology 39, 1–5 (2004).
   PubMedGoogle Scholar
• Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 233, 374–381 (1997).
   PubMedGoogle Scholar
• Wong DKH, Yuen MF, Poon RTP et al. Quantitation of HBV covalently closed circular DNA in HCC patients. Program and Abstracts of the 39th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany, 14–18 April (Abstract 382).
   Google Scholar
• Colin JF, Cazals-Hatem D, Loriot M et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29, 1306–3610 (1999).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Dieterich D, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the USA. Clin. Gastroenterol. Hepatol. 2(2), 87–106 (2004).
   PubMed Web of Science ®Google Scholar
• Brook M, Gilson R, Wilkins E, on behalf of the British HIV Association. BHIVA guidelines: coinfection with HIV and chronic hepatitis B virus. HIV Med. 4(Suppl. 1), 42–51 (2003).
   PubMedGoogle Scholar
• Nunez M, Lana R, Mendoza J et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27, 426–431(2001).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Treating opportunistic infections among HIV-infected adults and adolescents. Morbid. Mortal. Wkly Rep. 53(rr 15), 1–112 (2004).
   Google Scholar
• Zylberberg H, Jiang J, Pialoux G et al. Interferon-α for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol. Clin. Biol. 20, 968–971 (1996).
   PubMedGoogle Scholar
• Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to interferon-α therapy? A statistical analysis of predictive factors. Hepatology 10, 761–763 (1989).
   PubMed Web of Science ®Google Scholar
• Di Martino V, Thevenot T, Colin J et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 123, 1812–1822 (2002).
   PubMed Web of Science ®Google Scholar
• Dore J, Cooper D, Barret C et al. Dual efficacy of lamivudine treatment of human immunodeficiency virus–hepatitis B coinfected persons in a randomized, controlled study (CAESAR). J. Infect. Dis. 180, 607–613 (1999).
   PubMed Web of Science ®Google Scholar
• Hoff J, Bani-Sadr F, Gassin M et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of antihuman immunodeficiency virus regimens. Clin. Infect. Dis. 32, 963–969 (2001).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 30, 1302–1306 (1999).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348, 808–816 (2003).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348, 800–807 (2003).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Thibault V, Vig P et al. Significant and sustained efficacy of adefovir dipivoxil after 4 years of treatment in chronic hepatitis B patients with lamivudine-resistant HBV and HIV co-infection virus. Digestive Diseases Week. New Orleans, LA, USA, 15–20 May (2004) (Abstract 1).
   Google Scholar
• Ying C, De Clercq E, Nicholson W et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J. Viral Hepat. 7, 161–165 (2000).
   PubMed Web of Science ®Google Scholar
• Gallant JE, Stasziewski S, Pozniak AL et al, for the 903 Study Group. Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patents: a randomized trial. J. Am. Med. Assoc. 292, 191–201 (2004).
   PubMed Web of Science ®Google Scholar
• Dore G, Cooper D, Pozniak AL et al. Anti-hepatitis B virus activity in HBV/HIV coinfected patients treated with tenofovir DF and lamivudine versus lamivudine alone; 144 week follow-up. Abstracts of the XV International AIDS Conference. Bangkok, Thailand 11–16 July 2004 (Abstract 3308).
   Google Scholar
• Dore GJ, Cooper DA, Pozniak AL et al. Efficacy of tenofovir DF in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. 189, 1185–1192 (2004).
   PubMed Web of Science ®Google Scholar
• Piketty C, Pellegrin I, Katlama C et al. Efficacy of tenofovir DF in hepatitis B virus in HIV-1 coinfected patients, the TECOVIR study. Abstracts of the 11th Conference on Retroviruses and Opportunistic Infection. San Francisco, CA, USA, 8–11February 2004 (Abstract 834).
   Google Scholar
• Benhamou Y, Katlama C, Rozembaum W et al. Anti-hepatitis B virus (HBV) activity of tenofovir DF in human immunodeficiency virus (HIV) coinfected patients. 54th Conference of the American Association for the Study of Liver Diseases. 24–28 October 2003 (Abstract 1155).
   Google Scholar
• Van Bömmef, Wunsche T, Schurmann D et al. A comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infection. Hepatology 38(Suppl. 1), 275A (2003) (Abstract 246).
   Google Scholar
• Saag M, Cahn P, Raffi F et al., for the emtricitabine 301A study team. Efficacy and safety of emtricitabine versus stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. J. Am. Med. Assoc. 292, 180–190 (2004).
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Dimou E, Papadimitropoulos V. Nucleoside analogs for chronic hepatitis B: antiviral efficacy and viral resistance. Am. J. Gastroenterol. 97, 1618–1628 (2002).
   PubMed Web of Science ®Google Scholar
• Gish RG, Leung NWY, Wright TL et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob. Agents Chemother. 46, 1734–1740 (2002).
   PubMed Web of Science ®Google Scholar
• Gish R, Leung N, Wang C et al. Antiviral activity, safety and incidence of resistance in chronically infected hepatitis B patients given once daily emtricitabine for 2 years. Abstracts of the 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, USA, 24–28 October 2003 (Abstract 838).
   Google Scholar
• Raffi F, Snow A, Borroto-Esoda K et al. Anti-HBV activity of emtricitabine in patients coinfected with HIV and hepatitis B virus. Abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France, 13–16 July 2003 (Abstract 215).
   Google Scholar
• Harris J, Snow A, Borroto-Esoda K et al. Emtricitabine therapy for hepatitis infection in HIV-1 patients coinfected with hepatitis B: antiviral response and genotypic findings in antiretroviral treatment naive patients. Abstracts of the 11th Conference on Retroviruses and Opportunistic Infection. San Francisco, CA, USA, 8–11 February 2004 (Abstract 836).
   Google Scholar
• Cooksley W, Piratvisuth T, Lee SD et al. Peginterferon α-2a: an advance in the treatment of HBeAg-positive chronic hepatitis B. J. Viral Hepat. 10, 298–305 (2003).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau G, Bonino F et al. Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206–1217 (2004).
   PubMed Web of Science ®Google Scholar
• de Man R, Wolters L, Nevens F et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34, 578–582(2001).
   PubMed Web of Science ®Google Scholar
• Chang T, Hadziyannis S, Cianciara J et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 36, 300A (2002) (Abstract 550).
   Web of Science ®Google Scholar
• Lai C, Leung N, Teo E et al. International multicenter trial of telbivudin, alone and in combination with lamivudine, for chronic hepatitis B: an interim analysis. Hepatology 36, 301A (2002) (Abstract 554).
   Web of Science ®Google Scholar
• Afdhal N, O’Brien C, Oshana S, Dunkle L. Potent anti-HBV activity of ACH-126,443 correlated with 14-day pharmacokinetics and safety: predictions for activity against YMDD mutant strains. Hepatology 36, 372A (2002) (Abstract 837).
   Google Scholar
• Seigneres B, Pichoud C, Martin P et al. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36, 710–722 (2002).
   PubMed Web of Science ®Google Scholar
• Deres K, Schroder C, Paessens A et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299, 893–896 (2003).
   PubMed Web of Science ®Google Scholar
• de Man R, Marcellin P, Habal F et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 32, 413–417 (2000).
   PubMedGoogle Scholar